Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Benchmark Initiates Coverage On Belite Bio with Buy Rating, Announces Price Target of $57

Benchmark Initiates Coverage On Belite Bio with Buy Rating, Announces Price Target of $57

Benchmark analyst Bruce Jackson initiates coverage on Belite Bio (NASDAQ:BLTE) with a Buy rating and announces Price Target of $57.

byBenzinga Newsdesk

July 1, 2022

1 minute read

Benchmark analyst Bruce Jackson initiates coverage on Belite Bio (NASDAQ:BLTE) with a Buy rating and announces Price Target of $57.

Why Is Dental Supplier Henry Schein Stock Trading Higher Today?

By Vandana Singh

November 13, 1:18 PM

Henry Schein Inc (NASDAQ: HSIC) reported Q3 FY23 sales of $3.16 billion, slightly missing the

HSIC

What’s Going On With Smartsheet Stock Thursday?

By Adam Eckert

June 8, 11:32 AM

Smartsheet Inc (NYSE: SMAR) shares are trading lower Thursday in the wake of the cloud based work management platform company's first-quarter results.

SMAR

VinFast Auto Shares Are Falling Today As EV Company Taps New Source Of Equity Funding

By Nabaparna Bhattacharya

October 20, 10:33 AM

VinFast Auto Ltd. (NASDAQ: VFS) shares are trading lower after the Vietnam-based electric vehicle (EV) manufacturer

VFS

Stifel Maintains Buy on Flowserve, Raises Price Target to $38

By Benzinga Newsdesk

January 20, 11:51 AM

Stifel analyst Nathan Jones maintains Flowserve (NYSE:FLS) with a Buy and raises the price target from $37 to $38.

FLS

Benchmark Initiates Coverage On Belite Bio with Buy Rating, Announces Price Target of $57

Related Posts

Why Is Dental Supplier Henry Schein Stock Trading Higher Today?

What’s Going On With Smartsheet Stock Thursday?

VinFast Auto Shares Are Falling Today As EV Company Taps New Source Of Equity Funding

Stifel Maintains Buy on Flowserve, Raises Price Target to $38